Liu Yi, Hu Mingxiu
Takeda Pharmaceuticals International Co., 35 Landsdowne St., Cambridge, MA, USA.
Pharm Stat. 2016 Jan-Feb;15(1):37-45. doi: 10.1002/pst.1724. Epub 2015 Nov 26.
In this paper, we propose a design that uses a short-term endpoint for accelerated approval at interim analysis and a long-term endpoint for full approval at final analysis with sample size adaptation based on the long-term endpoint. Two sample size adaptation rules are compared: an adaptation rule to maintain the conditional power at a prespecified level and a step function type adaptation rule to better address the bias issue. Three testing procedures are proposed: alpha splitting between the two endpoints; alpha exhaustive between the endpoints; and alpha exhaustive with improved critical value based on correlation. Family-wise error rate is proved to be strongly controlled for the two endpoints, sample size adaptation, and two analysis time points with the proposed designs. We show that using alpha exhaustive designs greatly improve the power when both endpoints are effective, and the power difference between the two adaptation rules is minimal. The proposed design can be extended to more general settings.
在本文中,我们提出了一种设计,该设计使用短期终点在期中分析时进行加速批准,并使用长期终点在最终分析时进行全面批准,同时基于长期终点进行样本量调整。比较了两种样本量调整规则:一种将条件检验效能维持在预定水平的调整规则,以及一种能更好解决偏差问题的阶梯函数型调整规则。提出了三种检验程序:在两个终点之间进行α分割;在终点之间进行α穷举;以及基于相关性采用改进临界值的α穷举。通过所提出的设计,证明了对于两个终点、样本量调整以及两个分析时间点,能严格控制族系错误率。我们表明,当两个终点均有效时,使用α穷举设计可大大提高检验效能,并且两种调整规则之间的效能差异最小。所提出的设计可扩展到更一般的情形。